Cipla reported a net profit of ₹686 crore for the quarter ended June, down 4% from ₹715 crore in the first quarter of FY22, mainly due to a sharp normalization in the contribution of the Covid portfolio. Its first-quarter revenue fell 2% year-on-year to ₹5,375 crore from ₹5,504 crore.
Vohra said that several antiretroviral (ARV) drugs used against HIV could potentially be used as boosters to some other drugs used against Monkeypox virus. “We are continuously testing them… At this time, we have no information that any of these drugs may be potentiating agents for monkeypox or some other indication,” he said.
Ebitda declined 15% yoy to ₹1,143 crore, while Ebitda margin declined 388 basis points to 21.3%. Cipla’s revenue in India fell 8.4% year-on-year to ₹2,483 crore.